Psycheceutical Bioscience, a cutting-edge biotech startup, is making significant strides in the treatment of PTSD and other neurological conditions. The company has developed a revolutionary topical drug delivery system called NeuroDirect, which allows for the direct delivery of psychedelic drugs to the brain without the traditional side effects.

Unlocking the Potential

NeuroDirect has the potential to be a game-changer in the field of neurology. Successful trials could pave the way for treating conditions like Parkinson’s, drug addiction, and traumatic brain injury using this groundbreaking technology.

The Visionary Team

Psycheceutical is backed by notable investors, including Shark Tank’s Kevin Harrington. Led by Mike Zapolin, a former Wall Street VP and chief visionary officer, the company is making significant strides in the field of psychedelic medicine delivery.

How NeuroDirect Works

NeuroDirect delivers drugs via a patch placed at the base of the neck, targeting free nerve endings. This triggers nerve impulses that travel to the spinal cord and brain. The patch releases a crystal structure that emits the frequency of psilocin, providing the benefits of a microdose of psilocybin without other effects.

A Potential Solution to the Opioid Epidemic

NeuroDirect’s potential impact extends beyond the treatment of neurological conditions. This innovative drug delivery system has the potential to disrupt the opioid and fentanyl crisis, providing an alternative for pain management that doesn’t lead to addiction.

Looking Ahead

The groundbreaking work of Psycheceutical Bioscience and their NeuroDirect system will be a hot topic at the upcoming Benzinga Cannabis Capital Conference in Chicago on September 27-28. Industry experts, researchers, and advocates will gather to discuss the latest advancements in cannabis and psychedelic medicine.

All information about the event is available at bzcannabis.com.

Source: PharmaVoice

Photo courtesy of Mike Zappolin